- THE AWARD
As in the prior year, the 2019 award programme is intended to recognise and support those individuals or their institutions who are making a difference in advancing the knowledge around ECP Immunomodulation, in the EMEA region, with one educational grant of €50,000. This year’s award programme continues to support research investigating pathways of ECP therapy’s unique immunomodulatory mechanisms while specifically preserving immune function.
The following types of projects will be considered:
∙ Basic, translational or outcomes-based research (examples could include, but are not limited to, mechanistic questions, cell populations involved, the analysis of existing clinical data and/or corresponding biomarker samples).
∙ Collaborative projects, in the meaning that research could be carried out by the applicant in collaboration with multiple institutions. This is intended to encourage pan-European collaborations.
The Investigator Award Committee, consisting of a group of Medical Scientists employed by Mallinckrodt Pharmaceuticals, will select applications based on the above-mentioned criteria, judging specifically the novelty and feasibility of submitted projects. Please see all terms and conditions specified below.
- CLOSING DATE
Applications will be accepted from now until 31st January 2019, Midnight
The winner of the award will be notified by 31st March 2019. Mallinckrodt might use the occasion of a congress symposium or third party meeting to present the award to the winner (or commend runners-up).
This site is intended for healthcare professionals in Europe (excluding France), LATAM, Singapore and Saudi Arabia.
Please verify your status below.